ANWFX | SUGYX | ANWFX / SUGYX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 16 years | 3 years | - |
Gain YTD | 16.283 | 13.904 | 117% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 5000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 145B | 2.93M | 4,948,805% |
Annual Yield % from dividends | 1.03 | 0.50 | 207% |
Returns for 1 year | 23.14 | 27.31 | 85% |
Returns for 3 years | -3.67 | 25.29 | -14% |
Returns for 5 years | 46.56 | N/A | - |
Returns for 10 years | 72.50 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
LGLRX | 39.68 | 0.07 | +0.18% |
Lord Abbett Growth Leaders R3 | |||
EGOIX | 19.09 | N/A | N/A |
Allspring Large Cap Core Inst | |||
GTLLX | 35.48 | -0.07 | -0.20% |
Glenmede Quant US Large Cap Gr Eq | |||
SHPAX | 21.31 | -0.14 | -0.65% |
Saratoga Health & Biotechnology A | |||
GIDCX | 7.32 | -0.09 | -1.21% |
Goldman Sachs Intl Eq Div & Prem C |